Please assess the completion status of the following clinical trial:

Trial Title: Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. - Age ≥ 18 years~2. - BMI 25-45 kg/m2~3. - T2DM~4. - Advanced CKD\* (last eGFR \<30 ml/min/1.73m2 in EHR or ESKD on dialysis prior to screening) or stage G3B/A2-3 CKD (eGFR 30 to \<45 ml/min/1.73m2 with albumin/creatinine ratio \>30 mg/g).~5. - Fulfill kidney transplant listing criteria except for one or more of the following reasons (1: uncontrolled diabetes \[A1c ≥9%); 2: severe obesity (BMI ≥ 40 kg/m2 or BMI 35-40 kg/m2 with waist circumference \>120 cm). See exclusion criteria for general contraindications used for transplant listing used by majority of U.S. transplant centers\].~6. - Ability to provide informed consent before any trial-related activities~7. - Access to a telephone~   * The cause of the CKD does not need to be due specifically to diabetes~Exclusion Criteria (General contraindications used for transplant listing used by majority of U.S. transplant centers)~1. - Active malignancy~2. - History of pancreatitis~3. - Active substance abuse~4. - Severe COPD~5. - Pulmonary fibrosis~6. - Symptomatic angina or recent myocardial infarction within 6 months~7. - Severe peripheral vascular disease~8. - Cirrhosis~9. - New York Health Association (NYHA) Class III-IV congestive heart failure~10. - Severe cognitive impairment~11. - Drug addiction~12. - History of non-adherence to therapy~13. - Active infection~14. - Expected life expectancy \< 5 years~    Additional exclusion criteria~15. - Type 1 diabetes mellitus~16. - History of diabetic ketoacidosis within the last 12 months~17. - Planning on undergoing bariatric surgery in next 9 months.~18. - Pregnant, breast-feeding, or planned pregnancy prior to the end of participation or not using adequate contraceptive measures~19. - Self-reported average consumption of \> 21 alcoholic beverages per week or binge drinking~20. - Psychiatric hospitalization in past year~21. - Principal investigator discretion (i.e. concerns about safety, compliance)~22. - Known or suspected allergy to trial medication~23. - Previous participation (i.e. randomized) in this trial~24. - Use of GLP1-RA or pramlintide within 90 days prior to screening~25. - Use of metformin (contraindicated with eGFR \< 30 ml/min/1.73m2)~26. - Use of DPP-4 inhibitors within 30 days prior to screening~27. - Personal or family history of medullary thyroid cancer, multiple endocrine neoplasia types 2A and 2B syndrome~28. - Last hemoglobin A1c ≥ 12% or A1c \<6% (to avoid risk of hypoglycemia) prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: ACTIVE_COMPARATOR): This arm will receive semaglutide.
- Placebo (Type: PLACEBO_COMPARATOR): This arm will receive placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues